IBB

Stock splits

$IBB chatter on StockTwits

• 
  Getting Big NP@GettingBigNPBullish24m

  $MCRB $XBI $IBB S-3 just dropped and I’m sure the FUD crew will be quick to scream “dilution/ATM incoming.” Reality: the prior S-3 was filed Aug. 8, 2023 and had a 3-year term, so it was expiring right around now. Today’s filing looks like a straightforward shelf replacement to preserve financing flexibility. An S-3 ≠ an offering. An ATM ≠ shares being sold.

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish3h

  $MCRB $XBI $IBB @RoelInTheGreen You say the company is worth way more than the current market cap, but the past has kept you from buying. Fair enough. So what price would actually make you pull the trigger? Are you buying yet at these levels, or is there a specific price where the risk/reward becomes too compelling to ignore?

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish5h

  $MCRB $XBI $IBB coiled up like a serpent waiting to strike 🐍 Bullish divergence showing up across the **4H, 1D, 1W AND 1M** timeframes. Feels like the fuse is lit… just waiting for the **BOOM.** C’mon management, get that deal across the finish line and let the PR fly. 💥📈

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish6h

  $MCRB $XBI $IBB Down 5% on a grand total of 6k daily volume

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish7h

  $MCRB $XBI $IBB Personally, I think the risk/reward is extremely compelling at a sub ~$50M market cap. ✅ No debt ✅ Cash runway into 2027 ✅ Breakthrough Therapy + Fast Track designations ✅ Strong SER-155 data ✅ Expansion into irEC, with management engaging potential partners, including companies with ICI franchises ✅ Management is considering sources of financing while evaluating the next steps for SER-155, suggesting they have multiple paths available to advance the program ✅ Directors chose stock options instead of annual cash compensation, further aligning themselves with shareholders I continue to believe a partnership or potentially even an acquisition is a very real possibility over the coming months. Patiently waiting 💰

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish8h

  $GNPX $IBB $XBI

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish9h

  $GNPX $GNPX $XBI $IBB The more I dig, the more interesting this setup looks. Earnings dropping soon! ✅ ~500k post-split shares outstanding (per the reverse split adjustment) ✅ No meaningful debt ✅ Strong cash position - $27+ CASH/share ✅ Collaboration with Roche Diagnostics to advance biomarker validation in NSCLC ✅ Multiple clinical catalysts ahead Very likely we see double digits 10+ in the coming weeks, if not days 🚀

  View on StockTwits ↗
• 
  The mann@clanBullish11h

  $MNKD The ignorant negative trolls ... ... need to Learn More. For the good of all Mannkind. 🇺🇲 $SPY 💪 $QQQ 👍 $IBB 🇺🇲

  View on StockTwits ↗
• 
  staugard@BIOTECH_GURUBullish18h

  $XBI $IBB

  View on StockTwits ↗
• 
  Robin Quinn@jewell6923h

  $LEGN re-entry did a b mkt on close today 8/12 08/12/2026 Buy LEGN LEGEND BIOTECH CORP FUNSPONSORED ADR 1 ADR REPS 2 ORD SHS 400 $20.65 -$8,260.00 More 04/14/2026 Sell LEGN LEGEND BIOTECH CORP FUNSPONSORED ADR 1 ADR REPS 2 ORD SHS 200 $18.46 $0.12 $3,691.88 More 04/13/2026 Buy LEGN LEGEND BIOTECH CORP FUNSPONSORED ADR 1 ADR REPS 2 ORD SHS 200 $17.685 -$3,537.00 at 1st glance, it looks like I am chasing it, but hidden within the numbers is a DOUBLE that it ended up G!V!NG !T BACK. the stock peaked at 36.18 on 6/2 (ahead of the tech doomsday 6/23, remember ) but this is biotech $IBB $XBI

  View on StockTwits ↗
• 
  Steve@Woodman71d

  $CLNN $IBB $XBI $ARKG Further info on Clene presentation today:

  View on StockTwits ↗
• 
  Steve@Woodman71d

  $CLNN $IBB $XBI $ARKG This is the perfect example of an “asymmetrical risk/reward” situation. The FDA has been essentially coaching CLNN management on how to best position their submission for accelerated approval. EVERYONE wants a breakthrough win in the fight against ALS. This may be it. I don’t see much downside risk at this price point even with a possible dilution towards the end of the year. IMHO, they have managed their funding needs tightly to date and have tried their best to minimize dilution effect on existing shareholders. Check out this write up. (Note: 2024= 2026 in attached)

  View on StockTwits ↗
• 
  Getting Big NP@GettingBigNPBullish2d

  $GNPX $XBI $IBB The more I dig, the more interesting this setup looks. ✅ ~500k post-split shares outstanding (per the reverse split adjustment) ✅ No meaningful debt ✅ Strong cash position - $27+ CASH/share ✅ Collaboration with Roche Diagnostics to advance biomarker validation in NSCLC ✅ Multiple clinical catalysts ahead Very likely we see double digits 10+ in the coming weeks, if not days 🚀

  View on StockTwits ↗
• 
  Jay Glenn@QumiaBullish2d

  $SLS $XBI $IBB @Stocktwits Can This Be Pinned Again? Current Post Has Errors.

  View on StockTwits ↗
• 
  Bill Day@Wildbil2d

  $IBB $SLS $XBI

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.